Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Beefs-Up Benefit Data For “Approvable” OTC Weight-Loss Drug Alli

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline is bolstering its data on low-dose orlistat with several studies connecting the weight-loss drug to a reduction in risk factors associated with co-morbid diseases

You may also be interested in...



Blame China? Experts Advise Congress, Industry Take A Wider View

The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say

Blame China? Experts Advise Congress, Industry Take A Wider View

The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say

FDA Tackles Observational Studies In Draft Health Claims Guidance

"Scientific conclusions from observational studies cannot be drawn about a relationship between a food component and a disease," FDA concludes in draft guidance for health claim petitioners

Topics

UsernamePublicRestriction

Register

PS099737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel